Terns's stock soars as analysts cheer leukemia data — and predict more gains
The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill.
Terns Pharmaceuticals price target raised to $20 from $17 at Oppenheimer
Oppenheimer raised the firm's price target on Terns Pharmaceuticals to $20 from $17 and keeps an Outperform rating on the shares. Terns reported an interim update on TERN-701's Phase 1 study in chronic myeloid leukemia, providing "encouraging" three month efficacy and safety data that reinforce confidence surrounding its differentiated profile over existing tyrosine kinase inhibitors, the analyst tells investors in a research note. The firm believes TERN-701's emerging profile supports development in earlier-line settings, and its three-month performance strengthens its optimism surrounding longer-term major molecular response data, expected in Q4 of 2025.
Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial
Terns Pharmaceuticals Inc.'s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an early-stage trial of a treatment for chronic myeloid leukemia.
Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst
Terns Pharmaceuticals is developing TERN-601, an oral GLP-1R agonist, which showed a placebo-adjusted weight loss of 4.9% in a phase 1 trial for obesity treatment. The company plans to initiate a phase 2 study for TERN-601 in 2025, creating a significant catalyst opportunity for investors. The company is also developing TERN-701 for chronic myeloid leukemia, with interim phase 1 data expected in December 2024, offering another investment opportunity.
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Viking Therapeutics isn't the only weight loss biotech out there. Terns Pharmaceuticals just published some good phase 1 clinical trial data.
Should You Invest in This Under-the-Radar Weight Loss Stock?
Terns Pharmaceuticals' early-stage weight loss asset just reported positive clinical trial results. Even though it's showing some promise, Terns remains a risky bet.
1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More
Terns Pharmaceuticals just reported some strong data from a phase 1 clinical trial. The data suggest that it might be able to make a highly tolerable weight loss drug.
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive
Terns Pharmaceuticals' TERN-601 shows impressive weight loss results in a phase 1 study, positioning TERN competitively in the obesity drug market. The commercial viability of TERN-601's manufacturing scalability could be an advantage over certain competitors like Novo Nordisk's Rybelsus. TERN has sufficient funds to support operations into 2026, and a recent $125M public offering could allow it to go further.
Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill
Terns Pharmaceuticals' weight-loss pill has proved effective in a small trial, but still has much to prove before it can compete with blockbusters Zepbound and Wegovy.
Terns Pharmaceuticals' stock soars 30% after biotech posts positive results in trial of weight-loss drug in pill form
Terns plans to move to a Phase 2 trial for its TERN-601 small-molecule GLP-1 receptor agonist and will submit the latest data to a coming scientific conference.
Terns Pharmaceuticals' oral obesity drug cuts weight by 4.9% in early study
Terns Pharmaceuticals said on Monday its oral obesity drug helped to reduce weight by an average of 4.9% in an early stage study, sending its shares surging 31% in premarket trading.
